Liso-cel CAR-T cost-effective as second-line treatment for advanced lymphoma: Healio

“In our study, we incorporated the often-overlooked societal costs associated with cancer treatment, which are typically neglected in cost-effectiveness analyses that focus solely on the health care sector-related expenses,” Mohamed Abou-el-Enein, MD, PhD, MSPH, associate professor of medicine at University of Southern California’s Keck School of Medicine, said in a press release.